24167-51-9

Basic information

• Product Name: 3-bromo-N,N-dimethylbenzamide
• Synonyms: 3-bromo-N,N-dimethylbenzamide;UKRORGSYN-BB BBV-064760;3-bromo-N,N-dimethylbenzamide(SALTDATA: FREE);N,N-Dimethyl 3-bromobenzamide
• CAS NO: 24167-51-9
• Molecular Formula: C₉H₁₀BrNO
• Molecular Weight: 228.1
• Product Categories: alkyl bromide
• Mol File: 24167-51-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 322.3°C at 760 mmHg
• Flash Point: 148.7°C
• Appearance: /
• Density: 1.417g/cm³
• Vapor Pressure: 0.000282mmHg at 25°C
• Refractive Index: 1.563
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -1.90±0.70(Predicted)
• CAS DataBase Reference: 3-bromo-N,N-dimethylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-N,N-dimethylbenzamide(24167-51-9)
• EPA Substance Registry System: 3-bromo-N,N-dimethylbenzamide(24167-51-9)

Safety Data

• Hazardous Substances Data: 24167-51-9(Hazardous Substances Data)

Usage

General Description

3-bromo-N,N-dimethylbenzamide is a chemical compound with the molecular formula C9H10BrNO. It is a brominated derivative of N,N-dimethylbenzamide, and is commonly used in organic synthesis and pharmaceutical research. The compound has a molecular weight of 235.08 g/mol and a melting point of 115-117°C. It is a white to off-white crystalline solid at room temperature, and is used as a reagent in the production of various organic and pharmaceutical compounds. Additionally, it has applications in the field of medicinal chemistry, where it is explored for its potential pharmacological properties.

InChI:InChI=1/C9H10BrNO/c1-11(2)9(12)7-4-3-5-8(10)6-7/h3-6H,1-2H3

Upstream product

• 585-76-2 m-bromobenzoic acid 
• 124-40-3 dimethyl amine 
• 127-19-5 N,N-dimethyl acetamide 
• 1711-09-7 3-bromobenzoyl chloride 

Downstream Products

• 3132-99-8 m-bromobenzoic aldehyde 
• 832114-07-5 N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 1613045-50-3 (Z)-N-(1-(3-bromophenyl)-1-(dimethylamino)-3-oxo-3-phenylprop-1-en-2-yl)-4-methylbenzenesulfonamide 
• 1613045-51-4 C₂₄H₂₃BrN₂O₃S 
• 1447932-29-7 N,N-dimethyl-1',2',3',4'-tetrahydro-[1,1'-biphenyl]-3-carboxamide 
• 1240286-33-2 {4-chloro-2-[(3-dimethylaminocarbonylphenyl)ethynyl]phenoxy}acetic acid 
• 1040751-80-1 C₁₇H₁₈N₄O₂ 
• 153435-27-9 3-N,N-dimethylcarbamoylphenyltri-n-butylstannane 
• 952527-19-4 2-(3-(dimethylcarbamoyl)phenyl)-4-methyl-penta-2,3-dienoic acid methyl ester 
• 952527-68-3 carbonic acid 3-(3-(dimethylcarbamoyl)phenyl)-1,1-dimethyl-prop-2-ynyl ester methyl ester 
• 952527-67-2 3-(3-hydroxy-3-methyl-but-1-ynyl)-N,N-dimethylbenzamide 
• 4885-18-1 3-bromo-N,N-dimethylbenzylamine 
• 90238-15-6 [(3-Bromo-phenyl)-difluoro-methyl]-dimethyl-amine 

Relevant articles and documents

Rational Design and Synthesis of Selective PRMT4 Inhibitors: A New Chemotype for Development of Cancer Therapeutics**

Protein arginine N-methyl transferase 4 (PRMT4) asymmetrically dimethylates the arginine residues of histone H3 and nonhistone proteins. The overexpression of PRMT4 in several cancers has stimulated interest in the discovery of inhibitors as biological tools and, potentially, therapeutics. Although several PRMT4 inhibitors have been reported, most display poor selectivity against other members of the PRMT family of methyl transferases. Herein, we report the structure-based design of a new class of alanine-containing 3-arylindoles as potent and selective PRMT4 inhibitors, and describe key structure–activity relationships for this class of compounds.

LXR MODULATORS

The present invention provides compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as modulators of liver X receptors (LXR), compositions comprising any of such novel compounds, methods of using these compounds or compositions as medicaments for prevention or treatment of diseases or disorders related to liver X receptor (LXR), as well as methods of preparing these LXR modulators and using them in the manufacture of medicaments.

PHENOXY ACETIC ACID DERIVATIVES

The present invention provides phenoxyacetic acid derivatives of Formula (I) for the treatment of CRTH2 related disorders and disease selected from asthma, atopic dermatitis and inflammatory dermatoses.